Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018834 | 0.95 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7025842 | 0.95 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7016929 | 0.95 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7019149 | 0.95 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7015149 | 0.94 | ALDH1A1 (0.53) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7017695 | 0.94 | ALDH1A1 (0.53) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7015283 | 0.94 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7020089 | 0.94 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9APDE10ANPSR1 | |
| SCHEMBL7020461 | 0.94 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9APDE10APDE3B | |
| SCHEMBL7020884 | 0.93 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9APDE10ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | claimed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | claimed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | ALDH1A1 4330/4885NPC1 747/4885RAB9A 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.